The American company Pfizer stated that the Covid-19 vaccine, which it developed in cooperation with Biontech, is 90.7 percent effective against cases that show symptoms in children aged 5 to 11 years, according to a brief document published on the website of the US Food and Drug Administration.
Pfizer released the document ahead of a major hearing scheduled for October 26 at which an advisory panel will discuss whether the vaccine should be approved for young children, Bloomberg News reported. The result of the effectiveness is based on an experiment that included approximately 2,250 children, according to the brief document.
In its brief documentation, Pfizer released new safety data from an additional 2,250 children who took part in the trial as part of an expansion of the study requested by the US regulator. The data did not find any new safety issues and the side effects observed were consistent with those previously observed with the vaccine.